CorpDigest
UnitedHealth Group Incorporated
Leadership History
4 leaders · Full leadership timeline
Last reviewed: 2026-06-03 · By Swet Parvadiya
UnitedHealth Group's $400.3 billion in fiscal 2024 revenue exceeds the GDP of Denmark. It places the company second on the Fortune 500 behind only Walmart, ahead of Apple, Amazon, Exxon, and every bank in the world. That scale was not achieved through global expansion — it was achieved almost entirely within the American healthcare system, which UnitedHealth has systematically penetrated through vertical integration across insurance, pharmacy benefit management, care delivery, and health information technology. The February 2024 Change Healthcare ransomware attack cost the company more than $3.1 billion in direct remediation costs, provider advance payments, and disruption expenses — the most financially damaging cyberattack in US healthcare history. Change Healthcare processed approximately one-third of all US medical claims, and its disruption halted payment flows for hospitals, physician practices, and pharmacies across the country for weeks. That single event demonstrated both the company's operational centrality to American healthcare and its concentration risk. Optum employs more than 60,000 physicians, nurse practitioners, and physician assistants across more than 2,000 care delivery sites. That physician headcount makes Optum one of the largest direct employers of medical professionals in the United States — comparable to the largest academic health systems. When UnitedHealthcare directs its members to Optum Health clinics, the revenue that would otherwise flow to competing healthcare providers stays within the UnitedHealth Group corporate structure. The assassination of UnitedHealthcare CEO Brian Thompson in December 2024 created both a direct leadership crisis and a public relations moment that exposed broad public resentment about the American health insurance industry's claims denial practices. The company's immediate response, the subsequent media coverage, and the longer-term policy implications of that event represent a reputational and regulatory risk that cannot be fully quantified in financial terms.
CEO (returned 2024)
Architect of UHG's transformation into a vertically integrated healthcare company. Built Optum from a small services division into a $200+ billion revenue platform. Returned as CEO in 2024 following the assassination of UnitedHealthcare CEO Brian Thompson.
Former CEO
Former GlaxoSmithKline CEO who led UHG through the Change Healthcare acquisition and integration, navigated the 2024 cyberattack crisis, and continued Optum's expansion into care delivery before stepping down.
Former CEO
Transformed United HealthCare from a regional HMO into a national healthcare giant through aggressive acquisitions and the vision of combining insurance with health services. Forced to resign over stock options backdating scandal, paying $468 million in restitution.
Founder and original CEO
Founded United HealthCare Corporation to acquire and professionalize struggling HMOs across the Midwest. Built the company from a small Minneapolis operation to a publicly traded national health insurer through relentless acquisition.
That concentration of market power is both UnitedHealth Group's defining achievement and its central vulnerability. This vertical integration — the technical language of antitrust economics would call it a potential instrument of anticompetitive foreclosure — sits at the heart of ongoing Department of Justice scrutiny that could eventually force structural changes to the company's architecture. The architecture of that platform — how each component generates revenue, what the margin profile looks like across segments, and how the pieces interact to compound internal value — is central to both the company's extraordinary financial performance and its deepening regulatory vulnerability. The economics depend critically on actuarial accuracy in risk adjustment, care management program effectiveness (which reduces avoidable hospitalizations and emergency use), and the adequacy of CMS benchmark rates relative to actual medical cost trends.
Humana's concentrated exposure to Medicare Advantage, which accounts for approximately 80% of its revenue, has created vulnerability during periods of adverse MA economics — notably 2023 and 2024, when medical cost trends exceeded industry-wide expectations — but the same concentration has generated deep operational expertise in senior care management, risk adjustment, and population health that UnitedHealthcare must match to maintain leadership. The aggregate competitive picture for UnitedHealth Group is one of extraordinary current market position combined with genuine medium-term structural vulnerability. Optum Health's care delivery business, operating increasingly on value-based risk contracts, generated higher margins on attributed Medicare populations where care management effectiveness drove medical cost savings. UnitedHealth Group entered the second half of the 2020s carrying a heavier burden of simultaneous challenges than at any point in its modern history, with legal, regulatory, reputational, and operational risks converging in a way that tests the resilience of the underlying business model rather than merely requiring tactical responses.
UnitedHealth Group has had a small number of long-tenured chief executives since Richard T. Burke founded the company in 1977. Burke led the company until 1988 and was succeeded by William W. McGuire, a pulmonologist who joined UnitedHealth in 1988 and became CEO in 1991. McGuire ran the company for 15 years and was forced to resign in December 2006 amid an SEC investigation into backdated stock options. Stephen Hemsley, who had been chief operating officer and president, became CEO in December 2006 and led UnitedHealth through more than a decade of growth, retiring as CEO in September 2017 while continuing as executive chairman. David Wichmann succeeded Hemsley and ran the company from September 2017 until his retirement on February 5, 2021. Andrew Witty, who had run Optum, became CEO on February 5, 2021 and led the company through the Change Healthcare cyberattack and Brian Thompson killing before stepping down in May 2025, when Hemsley returned to the CEO role.
William McGuire resigned as UnitedHealth Group chairman and CEO in October 2006 and formally departed in December 2006 after an internal investigation found that stock option grants to him and other senior executives had been backdated, meaning grant dates had been selected with hindsight to coincide with low stock prices and inflate value. The probe, led by attorney William G. Wilkins and overseen by independent directors, followed a Wall Street Journal investigation and a Securities and Exchange Commission inquiry into option grant timing across multiple US companies. McGuire ultimately surrendered options worth approximately $620 million and paid a $7 million civil penalty to settle SEC charges in 2007, then paid additional sums in private securities litigation. The board also clawed back exercised gains and reformed governance practices. McGuire had grown UnitedHealth's revenue from roughly $400 million in 1991 to about $71 billion in 2005, and the scandal ranked as one of the largest options backdating cases in US corporate history, though McGuire admitted no wrongdoing and avoided criminal charges.
Stephen Hemsley took over as CEO in December 2006 in the wake of the McGuire options backdating scandal and led UnitedHealth Group through one of the largest expansions in US corporate history. Revenue grew from about $71 billion in 2006 to roughly $201 billion by 2017, more than doubling during the decade and surpassing every other US health insurer. Hemsley executed the 2011 consolidation of Ingenix, OptumHealth, and Prescription Solutions under the Optum master brand, transforming services into a coequal segment to UnitedHealthcare. He completed the 2015 Catamaran acquisition that lifted OptumRx into the top three pharmacy benefit managers. He navigated the company through the Affordable Care Act implementation, initially expanding then largely withdrawing from individual exchanges by 2017. Hemsley also rebuilt the executive bench, promoting David Wichmann to president in 2014, and oversaw the company's 2013 inclusion in the Dow Jones Industrial Average. He retired as CEO in September 2017, continuing as executive chairman, and returned to the chief executive role in May 2025.
Andrew Witty, the former GlaxoSmithKline CEO who became UnitedHealth Group CEO in February 2021, retired effective May 13, 2025 amid a cluster of crises that pressured the company through 2024 and into 2025. The February 2024 Change Healthcare cyberattack cost the company $2.45 billion and exposed protected health information for approximately 190 million Americans. The December 2024 killing of UnitedHealthcare CEO Brian Thompson drew sustained public criticism of claim denial practices. First quarter 2025 results missed expectations as Medicare Advantage utilization spiked, the medical care ratio climbed toward 89 percent, and the company withdrew full-year guidance in May. Reports emerged of a Justice Department criminal investigation into Medicare Advantage billing practices alongside ongoing civil antitrust review of Optum. The board appointed Stephen Hemsley, who had served as CEO from 2006 to 2017 and continued as chairman, to return as chief executive. Witty cited personal reasons but the timing tied closely to the operational and reputational pressure, and the company committed to a reset focused on pricing discipline and slower acquisition pace.